Company’s 36-month beta value is 1.04.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRUS is 66.31M, and currently, short sellers hold a 7.01% ratio of that floaft. The average trading volume of MRUS on June 20, 2025 was 1.20M shares.
MRUS) stock’s latest price update
Merus N.V (NASDAQ: MRUS)’s stock price has dropped by -0.92 in relation to previous closing price of 53.08. Nevertheless, the company has seen a loss of -4.47% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-11 that MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX’s durability argument and deep response rates could drive long-term value if validated in future studies.
MRUS’s Market Performance
Merus N.V (MRUS) has experienced a -4.47% fall in stock performance for the past week, with a 27.15% rise in the past month, and a 11.89% rise in the past quarter. The volatility ratio for the week is 0.86%, and the volatility levels for the past 30 days are at 7.72% for MRUS. The simple moving average for the past 20 days is -2.46% for MRUS’s stock, with a 13.43% simple moving average for the past 200 days.
Analysts’ Opinion of MRUS
Many brokerage firms have already submitted their reports for MRUS stocks, with Piper Sandler repeating the rating for MRUS by listing it as a “Overweight.” The predicted price for MRUS in the upcoming period, according to Piper Sandler is $84 based on the research report published on February 13, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see MRUS reach a price target of $91. The rating they have provided for MRUS stocks is “Overweight” according to the report published on February 07th, 2025.
Goldman gave a rating of “Buy” to MRUS, setting the target price at $73 in the report published on November 21st of the previous year.
MRUS Trading at 12.26% from the 50-Day Moving Average
After a stumble in the market that brought MRUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.50% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRUS starting from Shuman Harry, who sale 4,000 shares at the price of $48.50 back on Mar 21 ’25. After this action, Shuman Harry now owns 11,002 shares of Merus N.V, valued at $193,990 using the latest closing price.
Shuman Harry, the VP Controller, PAO of Merus N.V, sale 2,500 shares at $54.00 during a trade that took place back on Aug 21 ’24, which means that Shuman Harry is holding 7,002 shares at $135,000 based on the most recent closing price.
Stock Fundamentals for MRUS
Current profitability levels for the company are sitting at:
- -5.5 for the present operating margin
- 1.0 for the gross margin
The net margin for Merus N.V stands at -5.07. The total capital return value is set at -0.47. Equity return is now at value -58.66, with -45.13 for asset returns.
Based on Merus N.V (MRUS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -134.35.
Currently, EBITDA for the company is -269.6 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 67.99. The receivables turnover for the company is 3.85for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.86.
Conclusion
In a nutshell, Merus N.V (MRUS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
